Aster Insights has announced the appointment of Dr. Anand Shah as chief executive officer, effective immediately. He succeeds Jim Gabriele, who has stepped down from his position. Gabriele and Shah have collaborated closely on a number of strategic, operational, and business development initiatives over the past six months, and they will continue to work together to ensure a smooth leadership transition.
As CEO, Dr. Shah will lead the company’s continued growth with a focus on advancing Aster Insights’ national academic research collaborations, developing novel discovery products and services, and strengthening its position as the partner of choice for the life sciences industry. In addition to being a renowned health policy leader at the nexus of life sciences and healthcare delivery and services, Dr. Shah also serves as an operating advisor at Clayton, Dubilier & Rice. He will continue to sit on the company’s board of directors.
“Anand is uniquely qualified to lead Aster Insights through this next chapter that will focus on deepening the company’s partnerships with research institutions and the biopharma community,” said Sandi Peterson, chairman of the board. “He brings decades of experience in serving patients and working within the scientific, regulatory, commercial, and payer communities to advance new medical innovations with the aim of accelerating safe and effective cures for patients. His clinical and public policy expertise will be vital to supporting the company’s mission to patients and academic and life science partners.”
“Over the past two years on the board, I have worked closely with the world-class team at Aster Insights as the company has secured its position as a leader in real-world oncology data informatics and discovery. I am excited to lead Aster Insights at such an important inflection point in the race to develop the next generation of cancer treatments and improve patient care,” said Dr. shah.
A national physician leader and health policy expert, Dr. Shah has extensive healthcare experiences at the highest levels of the U.S. government, industry, academia, and as an oncologist. He was formerly the deputy commissioner for medical and scientific affairs at the U.S. Food and Drug Administration. Dr. Shah was responsible for developing and leading high-level FDA policy initiatives and oversaw cross-agency efforts in support of FDA’s public health mission.
At the Centers for Medicare & Medicaid Services, Dr. Shah served in two roles. As senior medical advisor, he was the primary counselor for agency-wide policy related to medical and scientific innovation. As the chief medical officer for the Center for Medicare & Medicaid Innovation, Dr. Shah led the clinical design of novel value-based payment and service delivery models, including those for primary and specialty care.
Read the full press release here.